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Frank J. Jenkins PhD 
DETECTION OF HHV-8 IN AUTOPSY SAMPLES FROM AIDS PATIENTS 
 
Lance Douglas Presser, M.S. 
University of Pittsburgh, 2007 
 
Human herpesvirus-8 (HHV-8), also known as Kaposi’s sarcoma-associated herpesvirus, 
is the most recently identified human herpesvirus.  A key question regarding HHV-8 is 
the location of infected cells within HHV-8 seropositive individuals.  Outside of tumor 
tissues, HHV-8 viral proteins have been detected in saliva, circulating B cells, and semen 
of some, but not all HHV-8 seropositive individuals.  HHV-8 is the causative agent of 
Kaposi’s sarcoma (KS) and is associated with two other distinct proliferative disorders: 
primary effusion lymphoma and some forms of multicentric Castleman’s disease.  To 
better understand viral infection including the cellular targets of infection, we have begun 
a systematic screening of autopsy tissues from HHV-8 seropositive men who died with 
AIDS.  Using immunohistochemistry (IHC), my goals were to determine reservoirs of 
HHV-8 infection and latency in organ tissues, determine the type of viral infection (lytic 
and/or latent) of each tissue type, and attempt to identify the infected cell type.  In this 
report, using IHC, we document the presence of HHV-8 infected cells in several organs 
including kidney, lung, liver, and gastrointestinal tract samples from the Multicenter 
AIDS Cohort Study (MACS).  Both lytic and latent infections have been detected and the 
infected cells appear to consist of both immune and non-immune cells.  These results 
demonstrate the ability of HHV-8 to establish infections in various organs which may 
affect the pathogenesis of the virus in infected individuals.  Kaposi’s sarcoma is currently 
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a major public health concern, as it is the most common malignancy found in individuals 
with AIDS and iatrogenic KS is a key concern in the field of solid-organ transplantation.  
This study will attempt to identify reservoirs of HHV-8 infection within the body in order 
to better understand the biology of HHV-8 in infected individuals, and the role HHV-8 
plays in disease pathogenesis. 
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1.0 INTRODUCTION 
 
1.1  HHV-8 
1.1.1  Discovery and associated cancers 
 
Human herpesvirus-8 (HHV-8), also known as Kaposi’s sarcoma-associated herpesvirus, is the 
most recently identified human herpesvirus.  HHV-8 was first identified in AIDS-KS tissue in 
1994 [1], and is required for the development of all forms of Kaposi’s sarcoma (KS) [2].  
Besides KS, HHV-8 is also etiologically linked to several rare types of lymphomas often found 
in AIDS patients, namely primary effusion lymphoma (PEL) and some forms of multicentric 
Castleman’s disease (MCD) [3].  
 
1.1.1.1  Kaposi’s sarcoma 
 
KS was first described as an “idiopathic multiple pigmented sarcoma of the skin” by Moritz 
Kaposi in 1872 [123]. KS is a multicentric angioproliferative disorder characterized by 
proliferation of spindle-shaped cells, neo-angiogenesis, inflammation, and edema [4-7].  There 
are four epidemiological variants of KS that develop in distinct populations of subjects: classic 
KS, endemic KS, AIDS-associated KS, and iatrogenic KS [8].  KS will be discussed more 
thoroughly in section 1.2 of this thesis. 
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1.1.1.2  Primary effusion lymphoma 
 
First identified as a subset of body-cavity-based lymphomas, primary effusion lymphoma (PEL) 
has been shown to contain HHV-8 DNA sequences [9].  The consistent presence of HHV-8 DNA 
in PEL implies an important role for HHV-8 in the pathogenesis of this rare lymphoma which 
accounts for only 0.13% of all AIDS malignancies in AIDS patients in the USA [10].  HHV-8 
DNA is always associated with PEL, and the majority of the cases are also EBV positive [11].   
 
1.1.1.3  Multicentric Castleman’s Disease 
 
HHV-8 is also linked to another B cell lymphoproliferative disorder called Multicentric 
Castleman’s Disease (MCD), which can be described by generalized lymphadenopathy with 
polyclonal hyperimmunoglobulinemia and high levels of serum IL-6 [12, 13].  Unlike KS and 
PEL, HHV-8 DNA sequences have only been detected in a subset of MCD patients, who are 
usually co-infected with HIV [13].   
 
1.1.2  HHV-8 prevalence and transmission 
 
The seroprevalence rates of HHV-8 in the general population vary depending on geographic 
location as shown by Figure 1.   
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 Figure 1.  Epidemiological patterns of HHV-8 infection. Countries were allocated to specific 
patterns on the basis of HHV-8 prevalence data.  For Mediterranean countries such as Greece, 
which lacks seroprevalence data, or Egypt, where data are available only for the city of 
Alexandria, allocation was based on patterns of KS occurrence.  The letters in the figure refer to 
HHV-8 genotype. (Figure reprinted with permission from Dukers, N.H. and G. Rezza, Human 
herpesvirus 8 epidemiology: what we do and do not know. Aids, 2003. 17(12): p. 1717-30.) 
 
HHV-8 seroprevalence is higher among HIV-seronegative homosexual subjects compared with 
the HIV-seronegative heterosexual population, ranging from 20% to 38% [14-16], and is even 
higher in HIV-seropositive homosexual populations, ranging from 30% to as high as 48% [17-
19].  In homosexual men who are seropositive for both HHV-8 and HIV, the presence of HHV-8 
DNA in peripheral blood mononuclear cells precedes and predicts the development of KS [20, 
21].  Currently virus has been detected most reproducibly in saliva [22, 23], and occasionally in 
genital secretions [22, 24-26].  These data show an important role for saliva in the transmission 
of HHV-8.   
  3
 Other modes of transmission have also been debated as some large cohorts of intravenous drug 
users and highly exposed hemophiliacs did not show increased seroprevalence over the general 
population [27, 28].  Other studies, however have detected a relationship between seropositivity 
and the frequency or duration of injection drug use [16, 29].  In the higher-prevalence societies 
of the Mediterranean Basin and Africa, a different epidemiologic pattern occurs.  Infection is 
equally prevalent in adult men and women, and infection begins in childhood. It is currently 
thought that saliva, possibly originating from the mothers’ premastication of food for child, and 
close interpersonal contacts, such as contact of non-intact skin or mucous membranes with blood 
containing secretions are the methods of transmission in endemic regions [30]. 
 
1.1.2.1  Sexual practices and HHV-8 infection 
 
Heterosexual transmission is not likely to be a major route and seems to require frequent sexual 
exposure to occur [31].  Prevalence seems to be elevated mainly in heterosexuals who have a 
high number of sexual partners or a sexually transmitted disease [32, 33].  Among homosexual 
men, there is agreement that the transmission of HHV-8 is primarily sexual in nature [14].  
However, the specific mechanism of transmission is still a topic of debate.  Some studies on the 
relationship between KS and sexual practices have reported an association between oral-anal sex 
and AIDS-KS [34, 35].  Cross-sectional studies have demonstrated an association between the 
presence of HHV-8 antibodies and anal-genital sex, oral-anal sex, and deep kissing with an HIV 
positive partner [22, 36, 37].  Currently virus has been detected most reproducibly in saliva [22, 
23], and occasionally in genital secretions [22, 24-26].  Anal-genital sex is a common practice 
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among homosexual men, as is oral-anal sex.  Therefore, if HHV-8 is present in saliva it may be 
transmissible by either of these two routes. 
 
1.1.2.2  HHV-8 epidemic and the AIDS epidemic 
 
KS was endemic in parts of Africa long before the beginning of the AIDS epidemic [38].  In 
these areas, and among populations of homosexual men in industrialized countries, widespread 
immunosuppression caused by HIV opened the door for HHV-8 to cause numerous cases of KS.  
Some studies conducted among homosexual men in North America and Europe suggested that 
there existed concurrent epidemics of HHV-8 and HIV infections and that the two infections 
potentially share modes of transmission [15, 36].  However, other studies suggested that the 
prevalence of HHV-8 infection was already high among homosexual men when the HIV 
epidemic began.  Although some initial increases in the prevalence of HHV-8 infection were 
reported among homosexual men at the start of the HIV epidemic, the prevalence has since 
remained nearly constant [39-41].  It has been suggested that this discrepancy in prevalence 
trends over time between HIV and HHV-8 indicate that there must be different or additional 
transmission routes for HHV-8 when compared to HIV [42].   
 
1.1.3  The genetic structure of HHV-8 
 
HHV-8 is a member of the lymphotropic γ-herpesviruses in the subfamily rhadinovirus [43].  
The HHV-8 genome is a double–stranded linear DNA of 165 to 170 kilobasepairs (kbp) [44].  
The genome contains a central unique region of approximately 137 kbp, which includes all of the 
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viral open reading frames, flanked by a series of highly GC-rich direct terminal repeats which 
make up the difference [44]. 
 
1.1.3.1  Phases of infection 
 
As with other herpesviruses, HHV-8 can establish either a latent or a lytic infection within 
infected cells.  During latency, the viral genome is maintained as a circular episome whose 
replication is coupled to cellular replication.  The few viral gene products that are expressed are 
important for maintaining the viral genome and for ensuring the survival of an infected 
population of cells.  No infectious virus is produced during latency, yet there is a clonal 
expansion of the infected population because viral replication is coupled to cellular replication.  
The cells that support latent replication are at risk for tumor development because viral proteins 
expressed during latency disrupt important regulatory pathways within the cell.   HHV-8 latent 
genes; latency associated nuclear antigen-1 (LANA-1), latency associated nuclear antigen-2 
(LANA-2), viral-cyclin, viral-FLICE inhibitory protein (v-FLIP), and kaposin have a widespread 
distribution in advanced AIDS-KS lesions [45].  v-FLIP is associated with anti-apoptotic activity 
[46], and activation of NF-kB by v-FLIP is associated with prolonged survival of HHV-8 
infected primary effusion lymphoma cell lines [47].  LANA-1 can antagonize p53-mediated 
apoptosis [48], and v-cyclin can inactivate tumor suppressor Rb and cyclin dependent kinase 
pathway inhibitor p27, thus promoting cell cycle progression [49].  LANA-1 and v-FLIP can also 
induce IL-6 secretion in HHV-8 infected cells [50, 51].  The kaposin gene also encodes several 
microRNAs (miRNA), which may regulate gene expression by binding to complementary 
messenger RNAs [52].   
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 Latently infected cells have the potential to shift to lytic replication.  Lytic replication is 
accompanied by expression of numerous viral proteins needed for making mature virions.  Cells 
supporting lytic replication are generally not at risk for malignant transformation because the 
host cell is usually destroyed when the replication cascade is complete, and hundreds of viral 
particles can be released from a single cell [53, 54].  Lytic replication is critical for transmission 
to uninfected cells, including dissemination to new hosts.  The production of infectious virus is 
often associated with a viral syndrome that results from multiple factors, including the altered 
function of newly infected cells, the lysis of infected cells, and the expression of viral gene 
products such as v-IL-6, and a viral-G protein-coupled receptor (v-GPCR), that have systemic 
and paracrine effects [55-57]. 
 
1.1.3.2  Relevant gene expression 
 
For the purposes of this thesis, we will focus on three major proteins (one latent phase, two lytic 
phase) expressed by HHV-8.  The latent phase protein of interest is the latency associated 
nuclear antigen type 1 (LANA-1).  The two lytic phase proteins we are observing are K8.1 and 
viral-interleukin-6 (v-IL-6). 
 
1.1.3.2.1  LANA-1 
 
The latency associated nuclear antigen type 1 (LANA-1) protein is a latent nuclear antigen of 
HHV-8 considered important in the establishment and maintenance of the HHV-8 latent viral 
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episome in the nucleus [58, 59].  LANA-1 is a 222-234 kDa protein that is expressed in the 
majority of nuclei in KS spindle cells [60, 61]; however, LANA-1 protein expression is variable 
and can depend upon the clinical stage of the KS tumor [60, 62]. 
 
1.1.3.2.2  K8.1 
 
The K8.1 glycoprotein is a structural component of the KSHV particle and is thought to play a 
role in virus entry by binding to heparan sulfate moieties on cell surfaces.  However, it has been 
shown that K8.1 is dispensable for HHV-8 entry [63].  K8.1 has a molecular weight of 35-40 
kDa and is unique to HHV-8 [64].  Two transcripts are produced, K8.1A and K8.1B, of which 
K8.1B is shorter.  K8.1A is very antigenic, and will be the form focused on in this study 
 
1.1.3.2.3  v-IL-6 
 
The role of IL-6 in KS and MCD had been suspected prior to the discovery of HHV-8 [44].  IL-6 
enhanced the proliferation of KS cells in culture and elevated levels of IL-6 corresponded with 
disease development in MCD [65, 66].  The HHV-8 homologue of IL-6, v-IL-6, shares roughly 
25% amino acid identity with the human cytokine, and has been shown to share similar 
biological properties with IL-6 [67]. 
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1.2  Kaposi’s sarcoma 
 
The most important disease state with which HHV-8 has been associated is Kaposi’s sarcoma 
(KS).  KS is an angioproliferative lesion that can occur in many tissues, but is most commonly 
localized to the skin [68].  Previously a rare disease, it is now a global and clinical health 
problem because of its association with the HIV pandemic and other immunosuppressed states.  
There are four epidemiological variants of KS that develop in distinct populations of subjects:  
classic KS, endemic KS, AIDS-associated KS, and iatrogenic KS [69, 70].  Classic KS is an 
indolent tumor that affects the elderly, primarily males, in Mediterranean countries such as Italy, 
Israel, and Turkey [71].  Classic KS legions are characteristically found in the lower extremities 
and typically are non-aggressive and non-lethal [70].  HHV-8 was prevalent in Africa prior to the 
HIV epidemic which was the cause of the large prevalence of KS seen on the continent before 
HIV changed the scope of KS presentations [72].  Endemic KS presents in four clinical forms 
with one form similar to classic KS, but found in younger adults; the other three forms are more 
aggressive, similar to AIDS-associated KS [70].  In the context of AIDS, KS is the most 
common malignancy and is an AIDS defining illness [73].  AIDS-associated KS is a more 
aggressive tumor than classic KS and can disseminate into the viscera with a greater likelihood 
of death [74].  AIDS-associated KS often presents multifocally and more frequently on the upper 
body and head regions [70].  In the context of immunosuppression, as with organ transplants, 
both primary infection and reactivation of HHV-8 becomes a potential concern.  It has been 
shown that post-transplant immunosuppression can cause iatrogenic KS to appear [75].  Post-
transplant KS can cause significant clinical manifestations such as rejection of the transplant 
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and/or death of the patient.  In a study of 356 post-transplant patients with KS, 40% had visceral 
involvement, and 17% of those with visceral KS died from the cancer [75].   
 
1.2.1  Prevalence 
 
KS has a much higher prevalence in areas endemic for HHV-8 such as Africa and Mediterranean 
countries [76-78].  Outside of these endemic areas, KS is most frequently seen in 
immunocompromised hosts, especially in patients with HIV who have a high rate of infection 
with HHV-8 [79, 80].  Only a small fraction of healthy adults infected with HHV-8 will ever 
develop symptomatic disease [81, 82].  This suggests that HHV-8 infection is necessary but not 
sufficient for the development of KS.  The disease is more likely to develop when there is 
dysfunction of the host immune system resulting from infection with HIV or from treatments to 
prevent organ transplant rejection.  Not all individuals who develop KS are overtly 
immunosuppressed, however.  Classic KS occurs primarily in elderly Mediterranean or 
Ashkenazi Jewish men who live in areas where seroprevalence is high [83].  In addition, men, 
women, and children in certain regions of Africa can develop an endemic form of KS without 
co-infection with HIV, but the incidence of KS in these regions increases when patients are also 
infected with HIV [78].   
 
1.2.2  At risk populations 
 
The incidence of KS after organ transplantation is 500-1000 times greater than in the general 
population [84].  Approximately 0.5 to 5% of organ transplant recipients develop KS, depending 
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on their geographical origin and the type of organ received [75].  HIV-infected individuals have 
a risk of KS that is thousands of times higher than that of the general population.  In a study of 
143 HIV-infected homosexual men, who were followed for a median of 30 months, more than 
50% of those who initially had HHV-8 sequences detectable by polymerase chain reaction in the 
peripheral blood mononuclear cells had progressed to KS within 3-5 years [20].  Studies of 
HHV-8 co-infected individuals with known dates of HIV seroconversion found a progression 
rate of nearly 30% after HIV seroconversion [85].  The hazard of KS from dual infection appears 
to increase by more than 27% for each year of infection with HIV before HHV-8 seroconversion 
[86].  These data suggest that KS among HIV-infected individuals is more likely to occur when 
an individual becomes more immunocompromised.  Also supporting this concept is the 
association between the progression to KS and low CD4 cell counts [86, 87].  Other indicators of 
the development of KS among HIV/HHV-8 co-infected individuals, such as high HHV-8 
antibody titres and high HHV-8 viral loads, have also been identified [87, 88].   
 
KS also seems to occur more often with HIV-1 infection, as compared to those infected with 
HIV-2, even when the two HIV types are accompanied by the same level of HHV-8 prevalence.  
These findings suggest that other co-factors specifically related to HIV-1, as opposed to HIV-2, 
are involved in the development of KS [89].   
 
There is very little information on the risk of KS development among immunocompetent HHV-8 
positive individuals.  This lack of information is due mostly to the low incidence of KS in the 
general population.  However, a study conducted among individuals over fifty years of age on 
three islands of the Mediterranean (Sardinia, Sicily, and Malta) showed yearly rates ranging from 
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1:3108 to 1:3574 among HHV-8 positive men and from 1:4,866 to 1:10,970 among HHV-8 
positive women.  The male to female ratio ranged between 1.4 and 3.5, suggestive of a role for 
gender-related factors in the development of KS [90].  How gender differences contribute to the 
risk of the development of KS remains undetermined. 
 
Other possible roles of other host-related factors also need to be additionally investigated.  These  
factors include malnutrition, especially in highly endemic areas of KS in Africa, or genetic 
factors that could either increase the risk of KS (HLA DR5) or decrease this risk (HLA DR3) 
[91, 92]. 
 
1.2.3  Gene expression 
 
The viral transcripts that are detected in most cells in KS lesions are primarily associated with 
latency.  These include LANA-1, v-cyclin, v-FLIP, and kaposin [46, 61, 93, 94].  LANA-1 is 
essential for latent replication of HHV-8 and for proper segregation of HHV-8 in daughter cells 
[58].  LANA-1 also affects important cellular regulatory proteins, including the tumor suppressor 
genes p53 and retinoblastoma gene product Rb [95, 96].  Due to the effects that LANA-1 has on 
p53 and Rb, latently infected cells are more likely to replicate both cellular and viral DNA and 
are less likely to undergo apoptosis, thereby increasing the population of latently infected cells.  
The v-cyclin expressed during latency stimulates cell division [97], and v-FLIP blocks apoptosis, 
enhancing survival of virally infected cells [47, 98].  As stated above, most cells in KS lesions 
are latently infected, however it has been reported that a few cells do continue to undergo lytic 
replication [99].  Some of the proteins expressed during lytic replication are currently 
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hypothesized to contribute to the tumorigenic phenotype.  v-GPCR, which is expressed early in 
the lytic cascade induces the expression of vascular endothelial growth factor (VEGF), a 
cytokine that is important in the angiogenesis that is characteristic in KS lesions [57]. 
 
1.2.4  HIV and HHV-8 crosstalk 
 
Recent studies have shown that HIV replication stimulates HHV-8 production in PEL cell lines 
and peripheral blood mononuclear cells from KS patients, possibly due to the activating 
functions of HIV-transactivation protein (Tat) [100].  ORF50, the major transactivator of HHV-8 
lytic cycle can in turn induce increased levels of HIV replication by interacting synergistically 
with HIV-1 Tat leading to increased cell susceptibility to HIV infection and transient 
permissiveness to HIV replication [101]. 
 
1.2.5  Previous reports of HHV-8 anatomical mapping
 
There have been numerous reports of different serological and PCR based assays for the 
detection of HHV-8 all with varying levels of sensitivity [102].  Even with these methods, a 
comprehensive anatomical mapping of HHV-8 had not been attempted, until recently.  A group 
from the University of Texas Medical Branch-Galveston attempted to anatomically map the 
reservoirs of infection of the eight human herpesviruses using fresh tissue specimens from forty 
major anatomical sites, from eight autopsies, using a recently developed real-time PCR method 
for detection of all eight human herpesviruses [103].  HHV-8 was detected in only two lymph 
nodes from two cases, a 43-year old HIV-positive male and a 73-year old HIV-negative male.  
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There were two major drawbacks to this study that our study was hoping to improve on.  The 
first was that there was no attempt to determine seroprevalence of the subjects used in the study.  
With a small n=8, there is a legitimate concern that none of the subjects were HHV-8 
seropositive.  With our study, seroprevalence was verified and all five of our subjects were 
seropositive for HHV-8. The second drawback, with any PCR based assay, is the inability to 
identify individual infected cells.  With IHC, individual infected cells can be visualized and a 
better knowledge of cell morphology and locations within tissues can be gained.  Therefore, the 
combined lack of mapping attempts, as well as the shortcomings of the above mentioned study, 
led us to the current study using IHC to anatomically map HHV-8 infection. 
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2.0  THESIS AIMS 
Human herpesvirus-8 (HHV-8), also known as Kaposi’s sarcoma-associated herpesvirus, is the 
most recently identified human herpesvirus.  A key question regarding HHV-8 is the location of 
infected cells within HHV-8 seropositive individuals.  Until recently, commercial reagents for 
the detection of this virus have not been available.  A small number of studies have been done 
trying to identify HHV-8 reservoirs within the body using PCR, but they have been ineffective 
due to various shortcomings as described in section 1.2.5. The rationale for using 
immunohistochemistry (IHC) to detect viral antigen in tissues of the autopsy cases was two-fold.  
First, IHC has been known to be sensitive and antibodies are available for the detection of HHV-
8 lytic and latent antigens.  Secondly, with IHC, individual infected cells are detected, which 
allows us to histologically attempt to determine infected cell types. Therefore, the overall goal of 
this study was to use IHC to gain a better understanding of HHV-8 reservoirs within HIV+, 
HHV-8+ individuals. 
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SPECIFIC AIMS 
Specific Aim #1:  Determine if the presence of HHV-8 infection will correspond to the known 
biology of the virus.   
Hypothesis:  We expect to see the virus in areas of high immune surveillance and lymphoid 
tissue concentration such as organs of the mucosa-associated lymphoid tissue as well as, gut-
associated lymphoid tissue. 
 
Specific Aim #2:  Determine what, if any, effect the presence of Kaposi’s sarcoma will have on 
the pattern and location of viral expression.   
Hypothesis:  KS status of the individual will have an effect on the prevalence and/or location of 
viral expression in the KS+ autopsy cases. 
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3.0  MATERIALS AND METHODS 
3.1  Sample selection criteria 
 
Samples were selected from Pittsburgh Multicenter AIDS Cohort Study (MACS) participants 
using the following criteria.  First, autopsy tissue had to be available from the patient.  Second, 
the patient had to be seropositive for HHV-8.  Using these criteria, a list of potential tissue 
donors was created and we randomly chose three patients without KS and two patients with KS.  
For each patient we received between twenty-three and thirty-four different tissue types.  
 
3.2  Immunohistochemistry 
 
Paraffin sections were cut at 5 µm and mounted on Surgipath microslides snowcoat X-tra.  The 
serial sections were deparaffinized in a 6-minute xylene wash and rehydrated in a series of 
ethanol grades to water starting with 2-five minute washes in 100% ethanol, followed by 1-5 
minute wash in 95% ethanol, 1-5 minute wash in 70% ethanol, and 2-5 minute washes in water.  
Antigen retrieval was performed using Target Retrieval Solution (Dako Cytomation Cat. 
#S1699) in a Black and Decker rice steamer for 40 (LANA-1) or 20 (v-IL-6, K8.1) minutes.  
Blocking of endogenous peroxidases was done in a 15 minute wash of 450 ml of methanol and 5 
ml of 30% hydrogen peroxide.  Non-specific proteins were blocked with either normal rabbit 
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serum (LANA-1) or normal goat serum (v-IL-6, K8.1) for 20 minutes at room temperature in a 
humidified chamber.  Anti-ORF 73 (anti-LANA-1) rat monoclonal, anti-ORF K8.1 mouse 
monoclonal, and anti-HHV-8 v-IL-6 rabbit polyclonal were used as primary antibodies at a 1:500 
dilution (ABI Cat. #13-210-100, 13-213-101, & 13-214-050 respectively).  Primary incubation 
occurred overnight at 4°C in a humidified chamber.  Biotinylated rabbit anti-rat IgG, goat anti-
mouse IgG, and goat anti-rabbit IgG were used as secondary antibodies (Vector Labs Cat. #BA-
400, BA 9200, & BA-1000 respectively).  Secondary incubation occurred for 60 minutes at room 
temperature in a humidified chamber.  Vector ABC Elite (Cat. #PK-7200) and Vector NovaRED 
substrate (Cat. #SK4800) were used to develop the staining.  Hematoxylin (Dako Cytomation 
Cat. #S3301) was used as the counter stain.  Slide mounting was done using Fisher Scientific 
permount (Cat. #SP15-100). 
 
3.3  Imaging 
 
Imaging was done using a Fisher Scientific USB 1.1 Digital/Video Micromaster II  
Brightfield microscope (Cat. # 12-563-313).  IHC stained paraffin slides were placed on the 
microscope stage and images were digitally captured using the Westover Scientific Micron 1 
imaging software program.  Image resizing and insets were done using Microsoft Photo Editor 
Version 3.0.2.3. 
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4.0  RESULTS 
4.1  Section I :  Description of autopsy cases and tissues received 
 
4.1.1  Description of autopsy cases 
 
The demographic information for each patient is shown in table 1. 
 
Patient #1 
 
Patient #1 was a 40 year old homosexual male who became seropositive for HIV in 1983 and 
enrolled in the Pitt Men’s Study in 1985.  He had a history of intravenous drug abuse and 
multiple sexual partners which put him at risk for developing AIDS.  No one entity was 
identified as the cause of death in this patient however, multiple organ failure due to 
cytomegalovirus (CMV) and HIV infection played a major role.  There were signs of nephritis 
which most likely resulted in renal failure, and pneumonia, coupled with bilateral pleural 
effusions, resulted in respiratory compromise.  His disease course was characterized by 
disseminated herpes zoster, CMV retinitis which resulted in blindness, multifocal 
leukoencephalopathy and decreasing CD4 counts.  Over the course of the disease he was treated 
with AZT, foscarnet and bactrim and he died in April, 1995. 
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 Patient #2 
 
Patient #2 was a 47 year old male who was diagnosed as HIV positive in March 1987, when he 
enrolled in the Pitt Men’s Study.  At his first visit in July 1987 his CD4 count was 511.  His CD4 
counts thereafter were always less than 200 and his most recent clinic visit in March 1993 
revealed a CD4 count of 30.  He had no significant family or social history.  He had a history of 
diarrhea, sinusitis, Candida infection, peripheral neuropathy, leukopenia, anemia and wasting.  
Upon autopsy, basal cell carcinoma of the anal canal and a poorly differentiated malignant 
neoplasm of uncertain origin in the oropharynx were discovered.  The cause of death was 
pneumonia, and gram negative septicemia, and the patient died in May, 1993. 
 
Patient #3 
 
Patient #3 was a 49 year old male, who was diagnosed with HIV in approximately 1985.  His 
only risk factor for HIV infection was homosexuality.  He had no history of intravenous drug use 
and was a nondrinker and a nonsmoker.  He was treated with AZT and prophylactic bactrim but 
stopped these medications due to side effects. He had a history of CMV retinitis, pneumonia due 
to Pneumocystis carinii and CMV.  Despite anti-viral therapy with foscarnet, anti-pneumocystis 
therapy with intravenous pentamidine and anti-fungal therapy with intravenous fluconazole, the 
patient had a downhill course and expired.  The cause of death was disseminated Cryptococcus, 
Pneumocystis carinii pneumonia (PCP) and CMV infection, and the patient died in July, 1995. 
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 Patient #4 
 
Patient #4 was a 45 year old homosexual male, who became seropositive for HIV in 1989.  He 
was diagnosed with AIDS in 1993 and Kaposi’s sarcoma in 1994.  The patient reported a 17 
pack/year history of smoking, quitting in 1989, and social alcohol use prior to 1989.  Postmortem 
examination revealed a large volume of melanotic stool distal to multiple jejunal ulcers.  The 
lungs were congested and both lower lobes had extensive discrete nodules that microscopically 
were consistent with a large cell lymphoproliferative disorder.  The neoplastic lymphocytes were 
within angiolymphatic spaces, consistent with a diagnosis of intravascular lymphomatosis.  
These abnormal lymphocytes were also seen in sections of liver, small and large bowel, and 
anus.  Kaposi’s sarcoma lesions were only seen grossly. Cause of death was bilateral pneumonia, 
lymphoproliferative disorder (LPD) involving lungs and colon, gastrointestinal hemorrhage and 
disseminated Kaposi’s sarcoma.  The patient died in January, 1994. 
 
Patient #5 
 
Patient #5 was a 40 year old homosexual male who tested positive for HIV in April 1984 when 
he joined the Pitt Men’s Study.  He was relatively asymptomatic until October 1990 when he 
developed PCP and oral Candidiasis.  In February 1992 he developed Kaposi’s sarcoma of the 
left chest wall which was treated by radiation therapy.  In August 1992, he was diagnosed with 
Mycobacterium avium complex disease.  Patient #3 was a smoker for 10 years but quit smoking 
in 1990.  He had no history of drug or alcohol abuse.  He had a history of Hepatitis B in 1977 or 
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1978.  Postmortem examination showed residual tumor at the site previously treated for Kaposi’s 
sarcoma on the left chest wall.  In addition, multiple lesions were seen in the rectum extending 
from the mucosa to the serosa.  There were also Kaposi’s sarcoma lesions in the lymph node, 
trachea and liver.  Cause of death was systemic Mycobacterium avium intracellulare complex 
infection complicated by multiple Kaposi’s sarcoma in the skin, rectum and liver and the patient 
died in June, 1993. 
 
Table 1.  This table shows an overview of the demographic information of each patient we 
received tissue samples from. 
Case # Age KS Status Date of Death Cause of Death HIV 
1 40 - 04/1995 CMV induced organ failure Seroconvert 
1983 
2 47 - 05/1993 Pneumonia and gram – 
septicemia 
Diagnosed 
1987 
3 49 - 07/1995 Disseminated Cryptococcus, 
PCP, and CMV 
Diagnosed 
1985 
4 45 + 01/1994 Pneumonia, LPD, GI 
hemorrhage, KS 
Seroconvert 
1989 
5 40 + 06/1993 Systemic Mycobacterium 
avium intracellulare 
Diagnosed 
1984 
 
4.1.2  Tissue received by case 
 
In this study we received tissue from five autopsy cases of men who were HHV-8 seropositive 
and died with AIDS.  Of the five cases, two of these men were diagnosed with KS.  The tissue 
samples that we received varied by case.  Tables 2 and 3 show what tissue types were received 
for each case. 
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 Table 2.  This table shows the autopsy tissue samples received from the three patients without 
KS. 
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 Table 3.  This table shows the autopsy tissue samples received from the two patients with KS. 
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4.1.3  Description of patient staining results 
 
Patient #1 (KS-) (Table 5) 
In patient 1, K8.1 staining was very prominent in the abdominal lymph node and this stain was 
the only staining seen in immune system tissue of patient 1.  In the major organs, K8.1 staining 
was seen sporadically in the kidney and spleen, and very prominently in the lung.  No v-IL-6 
staining was observed in any of the major organs.  In the upper GI, K8.1 staining was observed 
in all tissues except the stomach, and v-IL-6 staining was seen in all upper GI tissues of patient 1.  
In the lower GI, K8.1 staining was very prevalent, as it was observed in all lower GI tissues of 
patient 1.  v-IL-6 staining was also prominent in the lower GI, as it was absent only from anus 
tissue.  No staining was observed in any of the nervous tissue.  Both K8.1 and v-IL-6 staining 
was quite heavy in testes tissue from patient one.  In the miscellaneous tissue, K8.1 staining was 
seen sporadically in a penile lesion and thyroid tissue, and focally in the adrenal and right atrium 
tissue, whereas v-IL-6 was seen sporadically in the adrenal tissue.  No LANA staining was done 
on this patient due to time constraints. 
 
Patient #2 (KS-) (Table 6) 
In patient 2, K8.1 staining of the immune system tissue was very prominent.  There was also 
some sporadic LANA staining in the bone marrow tissue we received.  This was the only LANA 
staining observed in patient 2.  K8.1 staining was seen in the lung, heart, and kidney tissue of 
patient 2.  In the lower and upper GI, K8.1 staining was very prevalent, as it was seen each tissue 
sample tested from these systems.  The only observed v-IL-6 staining within patient 2 was seen 
in the testes tissue.  K8.1 staining was also observed in two vocal cord lesions in patient 2. 
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Patient #3 (KS-) (Table 7) 
In patient 3, lytic staining of the bone marrow tissue was very prominent, whereas in the lymph 
node, only LANA staining was observed.  K8.1 staining of the major organs was seen in the 
lung, spleen, and kidney of patient 2, with v-IL-6 being observed only in the kidney.  LANA 
staining was seen more prominently in patient 3 and was observed in the liver and kidney of 
patient 3.  In the upper and lower GI, lytic antigen staining was highly prevalent, especially K8.1 
in the lower GI, where all three tissues were of the highest staining level.  LANA staining was 
also observed in the lower GI in the colon and jejunum.  Similar to patient 1, no staining was 
observed in the nervous system tissue we received from patient 3.  In the testes tissue we 
received, only v-IL-6 staining was observed. 
 
Patient #4 (KS+) (Table 8) 
Patient 4 was found to be a special case and will be discussed further in the results section.  K8.1 
staining was seen to be very prevalent in the lymph nodes, as well as the upper and lower GI 
tissues of patient 4.  It was also observed in some of the organs such as the kidney and lung 
tissue.  v-IL-6 was seen less prominently than K8.1, but was observed in the lung, testes, and 
some of the lower and upper GI tissues.  LANA staining was also quite prevalent in patient 4, 
and was seen in the lung and kidney tissue, as well as in some of the upper and lower GI tissue. 
 
Patient #5 (KS+) (Table 9) 
In patient 5, LANA staining was observed in the bone marrow, kidney, esophagus, and three of 
the tissues of the lower GI.  K8.1 staining was less prevalent in patient 5 and was seen 
prominently in the lower GI, but seldom elsewhere.  v-IL-6 staining was very prevalent in the 
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major organs and was seen in lung, liver, and kidney tissue.  Elsewhere it was only observed in 
the prostate and ileum. 
 
4.2  Section II:  Immunohistochemistry Data 
 
IHC 
 
Using IHC our goal was to determine reservoirs of HHV-8 infection and latency, determine the 
type of viral infection (lytic and/or latent) of each tissue type, and attempt to identify the infected 
cell types.  In this report, using IHC, we document the presence of HHV-8 infected cells in 
several organs including kidney, lung, liver, and gastrointestinal tract samples from the 
Multicenter AIDS Cohort Study (MACS).  Both lytic and latent infections have been detected 
and the infected cells appear to consist of both immune and non-immune cells. 
 
4.2.1  Control Staining 
 
Our control slides, which were done in parallel with the staining of the tissue slides, consisted of 
a 2:1 mixture of BCBL/BJAB cells.  BCBL-1 cells are a body cavity based lymphoma cell line 
that is infected with HHV-8.  BJAB cells are a Burkitt Lymphoma cell line that is HHV-8 
uninfected.  Serial slides were done in duplicate and stained with either the primary antibody or a 
normal serum control.  Staining with the anti-LANA-1 antibody shows a nuclear stain, whereas 
staining with anti-v-IL-6 and anti-K8.1 antibodies show a cytoplasmic stain, with a visible 
nucleus.  Figures 2-7 are examples of each of these control stains. 
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 Figure 2.  BCBL/BJAB Normal Rat Serum 40x 
 
Figure 3.  BCBL/BJAB LANA-1 40x (Inset 100x) 
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 Figure 4.  BCBL/BJAB Normal Rabbit Serum 40x 
 
Figure 5.  BCBL/BJAB v-IL-6 40x (Inset 100x) 
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 Figure 6.  BCBL/BJAB Normal Mouse Serum 40x 
 
Figure 7.  BCBL/BJAB K8.1 40x (Inset 100x) 
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4.2.2  Semi-quantitation 
 
In order to be able to compare the IHC staining between samples, we developed a semi-
quantitative scale for the positive samples with five levels of staining.  Level 0, represents a 
negative staining and is characterized by absolutely no staining observed on the entire slide.  
Level 1, termed sporadic, represents staining of <25 cells scattered throughout the entire slide 
with no apparent foci.  Level 2, termed focal, represents staining of small clusters of cells 
dispersed throughout the slide.  Level 3, termed diffuse 1 represents staining similar to sporadic 
in the sense that there were no apparent foci; however, diffuse 1 overall has more positive 
staining than sporadic.  Level 4, termed diffuse 2, was the most positive category, with many 
positive cells densely spread throughout the sample.  Figures 8-15 show examples of each 
staining category. 
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Level 1:  Sporadic Example 
 
Figure 8.  Patient 4 Lung Normal Rabbit Serum 10x 
 
Figure 9.  Patient 4 Lung v-IL-6 10x (Inset 100x) 
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Level 2:  Focal Example 
 
Figure 10.  Patient 3 Muscle Normal Mouse Serum 10x 
 
Figure 11.  Patient 3 Muscle K8.1 10x (Inset 100x) 
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Level 3:  Diffuse 1 Example 
 
Figure 12.  Patient 2 Bone Marrow Normal Mouse Serum 10x 
 
Figure 13.  Patient 2 Bone Marrow K8.1 10x (Inset 100x) 
  34
Level 4:  Diffuse 2 Example 
 
Figure 14.  Patient 3 Jejunum Normal Mouse Serum 10x 
 
Figure 15.  Patient 3 Jejunum K8.1 10x (Inset 100x) 
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4.2.3  IHC Patient Samples 
Samples from each patient were chosen to represent the types of staining seen with different 
tissue types.  Figures 16-55 are tissue samples from each patient chosen as examples. 
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 Figure 16.  Patient 1 Esophagus Normal Mouse Serum 40x 
 
Figure 17.  Patient 1 Esophagus K8.1 40x (Inset 100x) 
Focal 
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 Figure 18.  Patient 1 Jejunum Normal Mouse Serum 40x  
 
Figure 19.  Patient 1 Jejunum K8.1 40x (Inset 100x) 
Diffuse 2 
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 Figure 20.  Patient 1 Left Kidney Normal Mouse Serum 40x  
 
Figure 21.  Patient 1 Left Kidney K8.1 40x (Inset 100x) 
Sporadic 
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 Figure 22.  Patient 1 Tongue Normal Mouse Serum 40x  
 
Figure 23.  Patient 1 Tongue K8.1 40x (Inset 100x) 
Diffuse 2 
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 Figure 24.  Patient 2 Bone Marrow Normal Mouse Serum 40x  
 
Figure 25.  Patient 2 Bone Marrow K8.1 40x (Inset 100x) 
Diffuse 2 
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 Figure 26.  Patient 2 Colon Normal Mouse Serum 40x 
 
Figure 27.  Patient 2 Colon K8.1 40x (Inset 100x) 
Diffuse 2 
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 Figure 28.  Patient 2 Left Upper Lobe Lung Normal Mouse Serum 40x 
 
Figure 29.  Patient 2 Left Upper Lobe Lung K8.1 40x (Inset 100x) 
Diffuse 1 
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 Figure 30.  Patient 3 Jejunum Normal Mouse Serum 40x  
 
Figure 31.  Patient 3 Jejunum K8.1 40x (Inset 100x) 
Diffuse 2 
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 Figure 32.  Patient 3 Muscle Normal Mouse Serum 40x 
 
Figure 33.  Patient 3 Muscle K8.1 40x (Inset 100x) 
Focal 
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 Figure 34.  Patient 3 Testes Normal Rabbit Serum 40x 
 
Figure 35.  Patient 3 Testes v-IL-6 40x (100x) 
Focal 
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 Figure 36.  Patient 4 Appendix Normal Rabbit Serum 40x 
 
Figure 37.  Patient 4 Appendix v-IL-6 40x (Inset 100x) 
Sporadic 
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 Figure 38.  Patient 4 Anal Skin Normal Rat Serum 40x 
 
Figure 39.  Patient 4 Anal Skin LANA-1 40x (Inset 100x) 
Diffuse 2 
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 Figure 40.  Patient 4 Anal Skin Normal Rabbit Serum 40x 
 
Figure 41.  Patient 4 Anal Skin v-IL-6 40x (Inset 100x) 
Diffuse 1 
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 Figure 42.  Patient 4 Colon Normal Rabbit Serum 40x 
 
Figure 43.  Patient 4 Colon v-IL-6 40x (Inset 100x) 
Diffuse 1 
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 Figure 44.  Patient 4 Right Lower Lobe Lung Normal Rabbit Serum 40x 
 
Figure 45.  Patient 4 Right Lower Lobe Lung v-IL-6 40x (Inset 100x) 
Sporadic 
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 Figure 46.  Patient 4 Foot Lesions Normal Rabbit Serum 40x 
 
Figure 47.  Patient 4 Foot Lesions v-IL-6 40x (Inset 100x) 
Diffuse 1 
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 Figure 48.  Patient 4 Right Lower Lobe Lung Normal Rat Serum 40x 
 
Figure 49.  Patient 4 Right Lower Lobe Lung LANA-1 40x (Inset 100x) 
Diffuse 2 
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 Figure 50.  Patient 4 Stomach Lesions Normal Rat Serum 40x  
 
Figure 51.  Patient 4 Stomach Lesions LANA-1 40x (Inset 100x) 
Diffuse 2 
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 Figure 52.  Patient 5 Ileum Normal Rabbit Serum 40x 
 
Figure 53.  Patient 5 Ileum v-IL-6 40x (Inset 100x) 
Diffuse 1 
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 Figure 54.  Patient 5 Liver Normal Rabbit Serum 40x 
 
Figure 55.  Patient 5 Liver v-IL-6 40x (Inset 100x) 
Diffuse 1 
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4.2.4  IHC results by case 
 
Tables 5-9 show which tissues of each patient tested positive and the level of staining as 
determined by semi-quantitation discussed earlier in this section.  Table 4 is the color legend that 
will be used in the following tables. 
 
Table 4.  Semi-quantitation legend. 
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Table 5.  Patient 1 IHC staining by tissue type and antigen 
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Table 6.  Patient 2 IHC staining by tissue type and antigen 
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Table 7.  Patient 3 IHC staining by tissue type and antigen 
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Table 8.  Patient 4 IHC staining by tissue type and antigen 
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Table 8. (cont.)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  62
Table 9.  Patient 5 IHC staining by tissue type and antigen 
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4.2.5  IHC results by organ system 
Table 10.  IHC staining of immune system tissue received from all patients 
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Table 11.  IHC staining of upper GI system tissue received from all patients 
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Table 12.  IHC staining of lower GI system tissue received from all patients 
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 Table 13.  IHC staining of the major organ tissue received from all patients 
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 Table 13. (cont.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  68
 Table 14.  IHC staining of the nervous system tissue received from all patients 
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 Table 15.  IHC staining of the reproductive system tissue received from all patients 
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 Table 16.  IHC staining of the misc. tissue received from all patients 
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5.0  DISCUSSION 
HHV-8 was first isolated from KS tissue in 1994 [1].  Since its discovery, it has been a priority 
to determine viral tropism in vivo, and thus far HHV-8 has been shown to naturally infect CD19+ 
B-cells [104], endothelium [105], monocytes [106], macrophages [107], dendritic cells [107], 
prostate glandular epithelium [108], and dorsal root sensory ganglion cells [109]. A 
comprehensive search for reservoirs of HHV-8 in the human body has not been attempted using 
IHC, and this study is the first of its kind.  Since HHV-8 is the causative agent of KS, PEL, and 
some forms of MCD, as well as suspected in other diseases, i.e., sarcoidosis [110], multiple 
myeloma [111], pemphigus vulgaris and pemphigus foliaceus [112], Kikuchi disease [113] and 
germinotropic lymphoproliferative disorder [114], it is of great importance to identify the 
reservoirs of HHV-8 within the human body.   
 
Like all other herpesviruses, HHV-8 has two phases of infection; lytic and latent phase.  It has 
been shown in vitro however, that expression of certain lytic proteins does not mean full lytic 
reproduction and progeny virus [115].  In a study done by Krishnan, H.H. et al. it was shown that 
lytic gene expression of HHV-8 is initiated soon after initial infection.  However, the initial lytic 
activation is not successful enough to proceed to a full-fledged lytic replication and progeny 
virus development.  Expression of only a subset of lytic cycle genes (K8.1 included) occurred 
and subsided rapidly thereafter [115].  While K8.1 staining still indicates viral infection, it may 
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not necessarily represent a reservoir of latency.  Therefore while K8.1, LANA-1, and v-IL-6 
staining all represent reservoirs of infection, only LANA-1 staining represents a reservoir of 
latency.
 
In this study, the majority of staining was of the two lytic antigens K8.1 and v-IL-6.  Lytic 
antigen staining was the most prevalent in the upper and lower GI sections.  There were a 
number of other tissues that stained positive for HHV-8 lytic antigens including lung, kidney, 
tongue, esophagus, etc.  These tissues are primarily tissues with high levels of immune 
surveillance and are part of the mucosa-associated lymphoid tissue system.  Based on the 
morphology of the cells staining positive for K8.1, we suspect that they represent immune cells, 
most likely macrophages.  In a separate study from our laboratory, we have demonstrated that 
macrophages, defined as CD68-positive cells, in the prostates of seropositive men expressed lytic 
antigens and therefore were infected with HHV-8 [116].  Preliminary data (not shown) from our 
lab shows that in some of these tissues (tongue, esophagus, colon, bone marrow, jejunum, and 
lung) the cells that are positive for K8.1 are also positive for CD68, a monocyte/macrophage 
marker.  HHV-8 has also been shown by other labs to infect macrophages with detectable 
expression of K8.1 [107].  If these are indeed macrophages, there are a few probable 
explanations.  The first explanation is that these are resident, non-inflammatory macrophages, 
i.e. alveolar macrophages, fixed bone marrow, macrophages, etc. that are getting infected and at 
the time of staining were expressing lytic proteins.  A second possibility is that cells within these 
tissues are infected with HHV-8 and the CD68+K8.1+ cells are inflammatory macrophages 
which have responded to HHV-8 infection and subsequently become infected themselves.  
Another explanation, a combination of the previous explanations, would be that the resident, 
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non-inflammatory macrophages are becoming infected initially, and are attracting circulating 
monocytes, which respond to the infection and subsequently become infected.  Without more 
immunostaining and individual cell identification it is difficult to know which of these scenarios 
is occurring.  However, due to location of staining in the body, morphology, and previous studies 
showing HHV-8 infection of macrophages, I believe that the most likely explanation is an initial 
infection of resident macrophages which then signal circulating monocytes via chemokines.  
These monocytes upon becoming inflammatory macrophages, and interaction with infected 
resident macrophages, become infected as well. 
 
In the first specific aim, my goal was to determine if the presence of HHV-8 infection will 
correspond to the known biology of the virus.  Our hypothesis was that we expect to see the virus 
in areas of high immune surveillance and lymphoid tissue concentration such as organs of the 
mucosa-associated lymphoid tissue as well as, gut-associated lymphoid tissue.  It is also 
important to note that the five subjects were all men who had sex with men, as this may play a 
role in how the virus has been transmitted.  As mentioned previously, HHV-8 has been shown to 
be most consistently detected in saliva and less consistently in semen.  Table 11 and 12 (upper 
GI and lower GI) show a high level of HHV-8 infection.  Expression of both lytic antigens was 
very prevalent among all subjects, while latent antigen expression was more confined to subjects 
four and five who are both KS positive.  Detection of viral infection was found from the tongue 
and proceeding through the trachea and esophagus leading to the lower GI tract.  These findings 
match well with the know ability for HHV-8 to be detected and transmitted in saliva.  In the 
lower GI, (Table 12) viral expression was very high, especially K8.1 which was detected in 
every tissue sample, from every patient with the exception of an anal skin sample from patient 
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five which was negative for v-IL-6 and LANA-1 as well.  Not only was K8.1 detected in these 
tissues, but the majority of the samples (21/25) scored in the top two (diffuse 1 or 2) staining 
categories.  v-IL-6 was detected in nine of the lower GI samples which fits well with the overall 
trend that v-IL-6 was seen less often than K8.1.  Of the thirty-three v-IL-6 positive samples, 
twenty-three were also positive for K8.1.  The major disparity of v-IL-6+, K8.1- samples was 
seen in the reproductive tissue where, of the five testes samples received, all five were v-IL-6 
positive, only one was K8.1 positive, and the lone prostate sample was vIL-6+, K8.1-.   
 
Another point of interest is the complete lack of HHV-8 antigen detected in the nervous system 
tissue (Table 14).  Although HHV-8 has been shown to infect dorsal root sensory ganglion cells, 
this study was unable to detect any viral antigen in any of the samples. 
 
Among the major organs, detection of HHV-8 was variable (Table 13).  Antigens were detected 
in bone marrow, lung, kidney, spleen, and heart tissue at varying degrees as well as in three of 
the five adrenal gland tissue samples.  From a public health standpoint, this is important to note 
when considering transplantation and the potential for iatrogenic infection of HHV-8 and post-
transplant seroconversion.  HHV-8 seroconversion has been documented in heart [117], kidney 
[118], liver [118, 119], and bone marrow transplant recipients [120].  No documentation of 
seroconversion in lung transplants was found, nor in the spleen, most probably due to rarity of 
spleen transplants.  With the potential for development of iatrogenic KS, transplant rejection, or 
even death, much has been made about potentially screening tissue donors for HHV-8 [121], or 
prophylactically treating with antiviral drugs before solid organ transplantation [122].  Our 
results from this study show that we did indeed find viral protein staining in tissues of high 
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immune surveillance and lymphoid tissue concentration, such as the lungs, gut-associated 
lymphoid tissue, and esophagus.  Therefore I believe that our results do correspond with the 
known biology of HHV-8 as well as provide new information about reservoirs of HHV-8 
infection and latency in the body.
 
In the second specific aim, it was our goal to determine what, if any, effect the presence of 
Kaposi’s sarcoma had on the pattern and location of viral expression.  Of the five patients, two 
were KS positive. In the reproductive and nervous system tissue there was no difference in 
detection.  There was no positive nervous system tissue samples (Table 13) and the reproductive 
tissue staining was very similar in every patient regardless of KS status (Table 15).  Looking at 
the results from the major organ tissue (Table 13), there doesn’t appear to be any great 
differences in viral antigen staining.  In the two patients with KS, lung, kidney, heart, liver and 
bile duct all were found to be positive for at least one viral antigen.  It was similar in the KS 
negative patients as HHV-8 antigen was detected in lung, kidney, heart, liver, and spleen.  The 
levels of positive staining were also quite similar between the two groups.  Lower and upper GI 
did show differences in LANA-1 expression between the two groups, as LANA-1 was expressed 
more often in the KS positive patients.  However, the lytic antigen expression between KS 
positive and KS negative patients for the upper and lower GI did not differ.  Based on these 
results, I feel that there was no major difference in prevalence of viral expression between KS+ 
and KS- subjects. 
 
Of special note in this thesis is patient four.  Upon review of the autopsy report, patient four was 
found to have had a large cell lymphoproliferative disorder known as intravascular 
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lymphomatosis, located in the bilateral lower lungs, liver, small and large bowel, and anus.  
Interestingly, LANA-1 staining of these tissues appeared to be associated with the cancer in the 
lungs, small and large bowel, and anus (no LANA-1 staining was observed in the liver of patient 
four) (Table 8, Figure 39, 49).  However, staining of a different block of liver tissue from the 
same patient, analyzed under a different study in our laboratory did find substantial staining in 
the lymphoma cells contained in the liver.  This is the first reported instance of HHV-8 being 
associated with intravascular lymphomatosis. 
 
5.1  Public health significance 
The use of IHC to detect reservoirs of HHV-8 infection and latency in the human body has not 
been attempted, and this is the first study of its kind.  This study is significant because we now 
have a more comprehensive idea of the reservoirs of HHV-8 infection and latency in HIV-
seropositive individuals.  Hopefully this study will lead to further studies with normal, 
immunocompetent individuals, and a better screening process for organ and tissue transplant. 
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6.0  FUTURE DIRECTIONS 
In the future, it will be important to identify specific cell types within the tissues that are HHV-8 
positive.  It has been difficult to identify cell type by merely histological means.  Therefore, in 
the future, it will be necessary to use further immunostaining methods to elucidate the specific 
cell types.   
 
Another aspect of this project that I feel should be considered is the potential that HIV and HHV-
8 are interacting and potentially co-localizing in the gut. Again, this will require more 
immunostaining for viral antigens of both viruses.  Studies have shown that HIV activity in the 
gut is quite high.  It has also been shown that HIV can evade treatment by “hiding” in the gut-
associated lymphoid tissue, and there is massive killing of immune cells that occurs in the gut 
with HIV infection.  There is a large amount of lymphoid tissue in the gut and as this study 
shows, there appears to be a trend of high HHV-8 lytic activity in the gut.  Therefore it seems a 
reasonable assumption that these two viruses may be interacting within the gut by way of their 
respective transactivator proteins (Tat, and ORF50) to induce viral protein production or viral 
replication. 
 
Finally, a similar study to this one should be done in healthy, HIV-seronegative individuals, 
preferably both men and women, as the severe immunocompromised state of these five patients 
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may have allowed for viral dissemination different from that seen in healthy, HIV-seronegative 
individuals. 
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